New CEO for Eden following conviction of JHL execs

Taiwan-based CDMO and biosimilars company Eden Biologics Inc. (formerly JHL Biotech) hired BMS alum Steve Lee as CEO and a director on the heels of the Aug. 26 convictions in the U.S. District Court for Northern California of JHL co-founders Racho Jordanov and Rose Lin of conspiracy to commit trade secret theft and wire fraud. The Department of Justice has entered into a non-prosecution agreement with Eden. In September 2019, JHL settled a civil suit involving allegations that the company stole Roche (SIX:ROG; OTCQX:RHHBY) unit Genentech Inc.’s trade secrets. JHL agreed to abandon development of biosimilar versions of Pulmozyme, Rituxan rituximab, Herceptin and Avastin. Before joining Eden, Lee was VP and general manager for process development and biologics manufacturing at Bristol Myers Squibb Co. (NYSE:BMY).

Genetic disease company Orchard Therapeutics plc (NASDAQ:ORTX) hired Fulvio Mavilio as CSO, and Nicoletta Loggia as CTO. Mavilio joins from Smart Immune, where he was CSO, and Loggia was most recently global head of cell and gene therapies, technical and research development at Novartis AG (SIX:NOVN; NYSE:NVS), where she held several roles for 17 years. Additionally, Leslie Meltzer was promoted to CMO from SVP of medical affairs, clinical operations and diagnostics...